JP2013538214A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538214A5
JP2013538214A5 JP2013526335A JP2013526335A JP2013538214A5 JP 2013538214 A5 JP2013538214 A5 JP 2013538214A5 JP 2013526335 A JP2013526335 A JP 2013526335A JP 2013526335 A JP2013526335 A JP 2013526335A JP 2013538214 A5 JP2013538214 A5 JP 2013538214A5
Authority
JP
Japan
Prior art keywords
syk
pharmaceutically acceptable
osteoclasts
optionally
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013526335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538214A (ja
JP5951610B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/003830 external-priority patent/WO2012025186A1/en
Publication of JP2013538214A publication Critical patent/JP2013538214A/ja
Publication of JP2013538214A5 publication Critical patent/JP2013538214A5/ja
Application granted granted Critical
Publication of JP5951610B2 publication Critical patent/JP5951610B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013526335A 2010-08-27 2011-07-29 トリアゾロピラジン誘導体 Expired - Fee Related JP5951610B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10008927.5 2010-08-27
EP10008927 2010-08-27
PCT/EP2011/003830 WO2012025186A1 (en) 2010-08-27 2011-07-29 Triazolopyrazine derivatives

Publications (3)

Publication Number Publication Date
JP2013538214A JP2013538214A (ja) 2013-10-10
JP2013538214A5 true JP2013538214A5 (enExample) 2015-07-16
JP5951610B2 JP5951610B2 (ja) 2016-07-13

Family

ID=44629489

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013526335A Expired - Fee Related JP5951610B2 (ja) 2010-08-27 2011-07-29 トリアゾロピラジン誘導体

Country Status (15)

Country Link
US (1) US9023851B2 (enExample)
EP (1) EP2609098B1 (enExample)
JP (1) JP5951610B2 (enExample)
KR (1) KR20130110163A (enExample)
CN (1) CN103068828B (enExample)
AR (1) AR082726A1 (enExample)
AU (1) AU2011295440B2 (enExample)
BR (1) BR112013004517A2 (enExample)
CA (1) CA2809331C (enExample)
EA (1) EA201300282A1 (enExample)
ES (1) ES2614128T3 (enExample)
IL (1) IL224869A (enExample)
MX (1) MX2013002198A (enExample)
SG (1) SG188296A1 (enExample)
WO (1) WO2012025186A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2674451T3 (es) * 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
HK1203948A1 (en) * 2012-03-07 2015-11-06 Merck Patent Gmbh Triazolopyrazine derivatives
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN104640850A (zh) * 2012-10-26 2015-05-20 霍夫曼-拉罗奇有限公司 3,4-二取代的1h-吡唑和4,5-二取代的噻唑的syk抑制剂
CN105026398B (zh) * 2013-03-05 2018-05-18 默克专利股份公司 用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物
WO2014135245A1 (en) * 2013-03-05 2014-09-12 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
CN105164136B (zh) * 2013-05-06 2017-12-22 默克专利股份公司 作为激酶抑制剂的大环化合物
WO2015017402A1 (en) * 2013-07-29 2015-02-05 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of biofilm infections
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
KR101756934B1 (ko) 2014-07-08 2017-07-12 연세대학교 산학협력단 피롤로[1,2-a]피라진 유도체, 이의 약학적으로 허용가능한 염, 이들 화합물의 제조방법 및 이를 유효성분으로 함유하는 골다공증 치료 또는 예방용 약학조성물
NZ754364A (en) 2016-12-22 2023-04-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115916747A (zh) * 2020-07-01 2023-04-04 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2434871C2 (ru) * 2005-02-03 2011-11-27 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиримидины, применимые в качестве ингибиторов протеинкиназы
JP4652906B2 (ja) * 2005-06-30 2011-03-16 富士夫 宮脇 振動型マイクロインジェクション装置
JP5256047B2 (ja) * 2006-01-27 2013-08-07 シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド ピロロ[3,2−c]ピリジン−4−オン2−インドリノン(indolinone)プロテインキナーゼ阻害剤
WO2008057994A2 (en) * 2006-11-03 2008-05-15 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2728893C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
AU2009259867A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
RU2560153C2 (ru) 2008-06-20 2015-08-20 Дженентек, Инк. Триазолпиридиновые соединения, ингибирующие jak, и способы
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
MX2011012961A (es) * 2009-06-05 2012-01-30 Cephalon Inc Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina.
PE20121511A1 (es) 2010-01-15 2012-12-06 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators

Similar Documents

Publication Publication Date Title
JP2013538214A5 (enExample)
US10568868B2 (en) Methods and compositions for treating metabolic reprogramming disorders
ES2761406T3 (es) Protección transitoria de células normales durante una quimioterapia
JP2013534227A5 (enExample)
JP2014526447A5 (enExample)
JP2014509313A5 (enExample)
ES2875584T3 (es) Formulación para inhalación líquida que comprende RPL554
US20180303838A1 (en) Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
AU2024219564A1 (en) Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
JP2013544781A5 (enExample)
ES2795879T3 (es) Aplicaciones terapéuticas de ectoína
UA121104C2 (uk) Гетероциклічні сполуки і їх застосування
US11980633B2 (en) Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
EA201491674A1 (ru) Новые фармацевтические композиции
JP2015505541A5 (enExample)
US20240293557A1 (en) Proteolysis targeting chimeras and methods of use thereof
CN105939717A (zh) 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法
US11844779B2 (en) PKC-Delta-I inhibitor formulations and uses thereof
KR101838764B1 (ko) (e)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형
ES2530223T3 (es) Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
US20240299558A1 (en) Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof
US20230241034A1 (en) Microtubule polymerization inhibitor prodrugs and methods of using the same
ES3023840T3 (en) Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
AU2008240118B2 (en) Methods for treating neoplasia with combination of chemotherapeutic agents and radiation
IT9022104A1 (it) Composizioni per la terapia mucolitica